OasisLMS

Beyond DOACs: Exploring the Promise of Factor XI Inhibitors in Cardiovascular Care

What You Will Learn

• Define the hemostasis and thrombosis.
• Compare and contrast the mechanisms of action of direct oral anticoagulants (DOACs) and investigational Factor XI inhibitors.  
• Explain DOACs and Factor XI inhibitors’ implications for thromboembolic risk and bleeding profile.
• Evaluate clinical trial data on the safety and efficacy of FXI inhibitors in various cardiovascular conditions, including AF, and secondary stoke prevention. 

We are grateful to these distinguished faculty who contributed to this collection:

Chair

Geoffrey D. Barnes, MD, MSc, FACC

Educational Grant Support Provided By: Bristol Myers Squibb and Janssen Pharmaceuticals, Inc., Alliance 

Page Launched: March 2026